AJTMH ASTMH MEMBERSHIP INFORMATION: astmh@astmh.org
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Am. J. Trop. Med. Hyg., 67(6), 2002, pp. 604-610
Copyright © 2002 by The American Society of Tropical Medicine and Hygiene

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Coulibaly, D
Right arrow Articles by Plowe, C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Coulibaly, D
Right arrow Articles by Plowe, C.
Related Collections
Right arrow Malaria
American Journal of Tropical Medicine and Hygiene, Vol 67, Issue 6, 604-610
Copyright © 2002 by American Society of Tropical Medicine and Hygiene

Research Articles


Impact of preseason treatment on incidence of falciparum malaria and parasite density at a site for testing malaria vaccines in Bandiagara, Mali

D Coulibaly, DA Diallo, MA Thera, A Dicko, AB Guindo, AK Kone, Y Cissoko, S Coulibaly, A Djimde, K Lyke, OK Doumbo, and CV Plowe

Treating malaria before immunizing has been standard in malaria vaccine field trials. To assess the impact of this practice on subsequent infection and disease incidence, we conducted a randomized cohort study in Bandiagara, Mali. Subjects received a treatment dose of sulfadoxine-pyrimethamine (SP) or no treatment at the beginning of the transmission season. Cumulative and age-specific incidence of clinical episodes was similar between the 2 groups, but SP treatment delayed the median time to first clinical episode from 38.5 to 68 days, and after this initial period of protection, disease incidence in the SP group quickly surpassed the incidence in the untreated group. Parasite densities during disease episodes were lower in the SP group. SP was chosen as the drug for initial parasite clearance for the following reasons: 1) it has been used in previous vaccine trials; 2) our studies have found it to have >99% efficacy in treating uncomplicated malaria in Mali compared to 85-90% efficacy for chloroquine in this area; 3) SP is the approved second-line antimalarial agent in Mali; and 4) its single-dose regimen ensures compliance when treatment is directly observed.


This article has been cited by other articles:


Home page
 Sci Transl MedHome page
S. L. Takala, D. Coulibaly, M. A. Thera, A. H. Batchelor, M. P. Cummings, A. A. Escalante, A. Ouattara, K. Traore, A. Niangaly, A. A. Djimde, et al.
Extreme Polymorphism in a Vaccine Antigen and Risk of Clinical Malaria: Implications for Vaccine Development
Science Translational Medicine, October 14, 2009; 1(2): 2ra5 - 2ra5.
[Abstract] [Full Text] [PDF]

Home page
 Am J Trop Med HygHome page
Y. CISSOKO, M. DAOU, K. E. LYKE, A. DICKO, I. DIARRA, A. KONE, A. GUINDO, K. TRAORE, G. KRISHNEGOWDA, D. A. DIALLO, et al.
SERUM ANTIBODY LEVELS TO GLYCOSYLPHOSPHATIDYLINOSITOLS IN SPECIMENS DERIVED FROM MATCHED MALIAN CHILDREN WITH SEVERE OR UNCOMPLICATED PLASMODIUM FALCIPARUM MALARIA AND HEALTHY CONTROLS.
Am J Trop Med Hyg, August 1, 2006; 75(2): 199 - 204.
[Abstract] [Full Text] [PDF]

Home page
 Am J Trop Med HygHome page
K. E. LYKE, A. DICKO, A. DABO, L. SANGARE, A. KONE, D. COULIBALY, A. GUINDO, K. TRAORE, M. DAOU, I. DIARRA, et al.
ASSOCIATION OF SCHISTOSOMA HAEMATOBIUM INFECTION WITH PROTECTION AGAINST ACUTE PLASMODIUM FALCIPARUM MALARIA IN MALIAN CHILDREN
Am J Trop Med Hyg, December 1, 2005; 73(6): 1124 - 1130.
[Abstract] [Full Text] [PDF]

Home page
 Infect. Immun.Home page
K. E. Lyke, R. B. Burges, Y. Cissoko, L. Sangare, A. Kone, M. Dao, I. Diarra, M. A. Fernandez-Vina, C. V. Plowe, O. K. Doumbo, et al.
HLA-A2 Supertype-Restricted Cell-Mediated Immunity by Peripheral Blood Mononuclear Cells Derived from Malian Children with Severe or Uncomplicated Plasmodium falciparum Malaria and Healthy Controls
Infect. Immun., September 1, 2005; 73(9): 5799 - 5808.
[Abstract] [Full Text] [PDF]

Home page
 Infect. Immun.Home page
C. Fluck, T. Smith, H.-P. Beck, A. Irion, I. Betuela, M. P. Alpers, R. Anders, A. Saul, B. Genton, and I. Felger
Strain-Specific Humoral Response to a Polymorphic Malaria Vaccine
Infect. Immun., November 1, 2004; 72(11): 6300 - 6305.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2002 by the American Society of Tropical Medicine and Hygiene.